Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients: A Machine Learning Approach by Ferroni, Patrizia et al.
For Peer Review
 
 
 
 
 
 
Risk assessment for venous thromboembolism in 
chemotherapy treated ambulatory cancer patients: a 
machine learning approach 
 
 
Journal: Medical Decision Making 
Manuscript ID Draft 
Manuscript Type: Original Manuscript 
Date Submitted by the Author: n/a 
Complete List of Authors: Ferroni, Patrizia; San Raffaele Rome University, IRCCS San Raffaele Pisana 
Zanzotto, Fabio; Universita degli Studi di Roma Tor Vergata, Department of 
Enterprise Engineering 
Scarpato, Noemi; San Raffaele Rome University 
Riondino, Silvia; IRCCS San Raffaele Pisana; Universita degli Studi di Roma 
Tor Vergata, Department Systems Medicine, Medical Oncology 
Nanni, Umberto; Universita degli Studi di Roma La Sapienza, Department 
of Computer, Control, and Management Engineering Antonio Ruberti 
Roselli, Mario; Universita degli Studi di Roma Tor Vergata, Department of 
Systems Medicine, Medical Oncology 
Guadagni, Fiorella; San Raffaele Rome University, IRCCS San Raffaele 
Pisana 
APPLICATION AREAS: ONCOLOGY 
DETAILED METHODOLOGY: 
Clinical Prediction Rules < CLINICAL RESEARCH METHODOLOGY, Risk 
Stratification < CLINICAL RESEARCH METHODOLOGY, Decision Support 
Techniques < INFORMATICS, Survival Analysis < STATISTICAL METHODS 
  
 
 
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
For Peer Review
Risk assessment for venous thromboembolism in chemotherapy treated ambulatory cancer 
patients: a machine learning approach
1
 
 
Running title  Machine learning for VTE risk prediction 
 
1
*Patrizia Ferroni, M.D., 
2
*Fabio Massimo Zanzotto, Ph.D., 
1
Noemi Scarpato, Ph.D., 
3,4
Silvia Riondino, M.D., 
5
Umberto Nanni, Ph.D., 
4
Mario Roselli, M.D., 
1,3
Fiorella Guadagni, M.D. 
 
*First authors for equal contribution 
 
1
San Raffaele Rome University, Via di Val Cannuta,247 Rome, Italy 
2
Department of Enterprise Engineering, University of Rome "Tor Vergata", Rome, Italy 
3
BioBIM (InterInstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana, Rome, Italy 
4
Department of Systems Medicine, Medical Oncology, University of Rome "Tor Vergata", Rome, Italy 
5
Department of Computer, Control, and Management Engineering Antonio Ruberti, Sapienza University, Rome, 
Italy 
 
Contact information 
Patrizia Ferroni   patrizia.ferroni@sanraffaele.it 
Fabio Massimo Zanzotto fabio.massimo.zanzotto@uniroma2.it 
Noemi Scarpato  noemi.scarpato@unisanraffaele.gov.it 
Silvia Riondino   silvia.riondino@sanraffaele.it 
Umberto Nanni   umberto.nanni@dis.uniroma1.it 
Mario Roselli   mario.roselli@uniroma2.it 
Fiorella Guadagni  fiorella.guadagni@sanraffaele.it 
 
Corresponding author 
Prof. Fiorella Guadagni, San Raffaele Rome University, Interinstitutional Multidisciplinary Biobank (BioBIM),  
SR Research Center, IRCCS San Raffaele Pisana, Via di Val Cannuta, 247, 00166 Rome - Italy  
Tel: +39 06 52253733; e-mail: fiorella.guadagni@sanraffaele.it; alternate e-mail: guadagnifiorella@gmail.com  
 
Keywords: Clinical decision support systems, machine-learning, random optimization, venous 
thromboembolism, cancer. 
Word count:  4366 
  
                                                           
1
Financial support for this study was provided in part by research funding from the European Social Fund, under the Italian 
Ministry of Education, University and Research PON03PE_00146_1/10 BIBIOFAR (CUP B88F12000730005). The funding 
agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the 
report. 
Page 1 of 29
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
ABSTRACT  
 
Objective:  To design a precision medicine approach aimed at exploiting significant patterns in data, in order to 
produce VTE risk predictors for ambulatory cancer patients that might be of advantage over the currently 
recommended model (Khorana score). 
Design:  Kernel machine and random optimization (RO) models were used to produce VTE risk predictors 
yielding the best classification performance over a training (3-fold cross validation) and testing set. 
Results:  Clinical attributes of the patient dataset were divided into 9 groups according to clinical significance. 
Our analysis produced 6 RO models in the training set, which yielded better hazard ratios (HRs) compared with 
baseline models (HRs ranging from 1.45 to 3.36) and were all significant in terms of VTE risk prediction. With 
only one exception, the superiority of these models over their baseline counterparts was validated in the 
testing set, in which the probability of VTE occurrence in patients classified as at-risk by 2 RO models (HRs 4.48 
and 6.92) was 2 to 3-fold higher than that observed using the pure Khorana score (HR 2.16). Of interest, the 
best fitting model was one in which the strongest weight was retained by blood lipids, body mass index and 
performance status, with a weaker association with tumor site/stage and drugs.  
Conclusions:  Although the monocentric validation of the predictors here presented might represent a 
limitation, these results demonstrate that a model based on kernel learning machines and RO may outperform 
the currently recommended score, and has the unquestionable advantage to be dynamically recalculated and 
integrated with local data. Moreover, this study highlights the advantages of optimizing the relative importance 
of groups of clinical attributes in the selection of VTE risk predictors. 
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INTRODUCTION 
In recent years, the approach to medicine has substantially changed: global approaches have been 
pressured by a growing availability of electronic health records (EHR) and by the consequent demand to 
provide precision medicine. The intuition is that precision medicine can produce better approaches to disease 
treatment and prevention by taking into consideration individual biological variability, environmental exposure 
and lifestyle. 
Oncology is a field that could significantly benefit from a precision medicine-based approach, both in the 
development of targeted therapies, which represent a key to successful patient treatment, and in other clinical 
contests, in order to improve treatment delivery and clinical outcome. 
One of the major challenges that oncologists are presently facing is the risk assessment of venous 
thromboembolism (VTE). The development of VTE, in fact, may result in treatment delays with detrimental 
effects on the overall outcome for cancer care and patient’s quality of life.
1
   Hence, the use of appropriate 
thromboprophylaxis in cancer patients treated with chemotherapy could provide an opportunity to 
substantially improve their clinical management.
2
 Nonetheless, all current consensus guidelines do not 
recommend routine prophylaxis for the primary prevention of VTE in ambulatory cancer patients receiving 
chemotherapy,
3,4
 although “it may be considered for selected high-risk patients” following “discussion with the 
patient about the uncertainty concerning benefits and harms”.
4
 These statements emphasize how selecting 
patients for prophylactic anticoagulation is perceived as a growing necessity in cancer patient management, 
fostering the demand for risk assessment models. 
Predicting VTE risk for cancer patients is, thus a compelling challenge where precision medicine can play a 
crucial role. In fact, VTE risk differs not only among patients, but even in the same patient over the course of 
cancer natural history.
5
  The highest risk is in the first 3-6 months after initial diagnosis possibly as a result of 
combined anti-cancer therapies in the same time range.
6,7
  
However, implementing an effective VTE risk predictor for cancer patients is very difficult. Khorana and 
colleagues developed and validated an interesting model for predicting chemotherapy-associated VTE using a 
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combination of routinely available variables.
8
 This model takes into account the site of cancer (2 points for 
very-high-risk stomach, or pancreas cancer; 1 point for high-risk lung, or genitourinary cancer and 0 point for all 
other solid cancer sites), platelet count ≥350 x 10
9
/L,  leukocyte count ≥11 x 10
9
/L, hemoglobin ≤10 g/dL and/or 
use of erythropoiesis-stimulating agents and body mass index (BMI) ≥35 kg/m
2
 (1 point each).
8
 To date, this is 
the sole model for VTE risk assessment in ambulatory cancer patients treated with chemotherapy.  As such, the 
Khorana score has been proposed in the guidance statement of the Scientific and Standardization Committee 
of the International Society for Thrombosis and Haemostasis.
9
 Nonetheless, although validated by independent 
groups,
10,11
 the Khorana score fails to classify 40% to 60% of patients (intermediate risk), in whom clinical 
decision making remains challenging.  Consistent with these observations, expanded risk scoring models, 
including either laboratory tests,
10
 or the anti-cancer drug used,
12
 were proposed.  Despite these efforts, VTE 
risk prediction for chemotherapy-treated cancer outpatients is still sub-optimal. 
A precision medicine approach might help to overcome many of the problems encountered so far.  
Nonetheless, the general problem of precision medicine, which arises also in the case of VTE risk prediction for 
oncological patients, is that this method considers a huge amount of clinical variables.
13
 This is both the power 
and a possible drawback of precision medicine and highlights the urgent need for a new generation of 
computational theories and tools to assist researchers in extracting knowledge from the growing volumes of 
digital data.
14
 
Based on these considerations, we hypothesized that machine-learning (ML) models can help in solving this 
problem. ML is gaining popularity in medicine and in bioinformatics,
15-19
 as it can derive patterns in clinical and 
biochemical knowledge (for a recent review see
20
). Moreover, ML has been also applied to learn VTE risk 
predictors for the general population,
21
 and could thus represent a solid base on which to build the next 
generation of precision medicine approaches in oncology. 
Therefore, aim of the present study was to analyze the performance of a different approach from that 
generally used in the development of risk assessment models based on the arbitrary assignment of a score 
according to association analyses (i.e. Khorana score). To this purpose, we used kernel learning machines,
22
 (as 
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suggested by Jensen and Bateman
23
) and random optimization (RO)
24
 to produce VTE risk predictors in a 
population of consecutive ambulatory cancer patients representative of a general practice cohort. These 
predictors exploit significant patterns in data – connoting causality between individual features and VTE – and 
can be used in the development of a clinical decision support system for VTE risk stratification of ambulatory 
cancer patient prior to chemotherapy start. 
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METHODS 
Learning VTE Risk Predictors within a Precision Medicine Approach 
In the context of precision medicine, we introduced a new methodology to produce VTE risk predictors that 
exploit personalized data. Our methodology is based on a particular class of learning machines, namely, kernel 
machines,
22
 and on a model to devise relative importance of different groups of clinical attributes in final 
prediction decisions, namely, RO.
24
 
VTE risk predictors are binary classifiers that, given a patient x, have to determine whether or not  x will 
develop a VTE event in the future. In ML (see
18
 for details), binary classifiers are functions f(x)=y that take as 
input instances x and emits a class y∈{1, -1}. Instances x are represented as vectors of feature values 
 = (, … , ). Hence, in our settings, x is a patient, and y=1 is the prediction of the occurrence of VTE in the 
future. Finally, each feature of vectors  represents one of the clinical attributes. Therefore, the challenge is to 
build binary classifiers that make a good use of the information stored in these vectors of feature values.  
Inducing binary classifiers f(x) by observing training data T is the major objective of ML. This activity is called 
learning. Hence, the output y of the learnt classifier depends on  x and on T, that is f(x,T). During learning, 
specific algorithms discover regularities in training data by comparing instances. In our study, we use a 
particular class of learning algorithms called kernel machines.
22
  These machines compare instances x
(a)
 and x
(b)
 
by doing a dot product between their unit vectors, that is, 〈(), ()〉. This dot product is called kernel and is 
often referred as (), (). The kernel of unit vectors is close to 1 if vectors are similar. Thus, roughly, 
kernel machines tend to classify novel examples by computing the similarity with training examples. In fact, the 
learnt function is: 
(, ) = 	(〈, 〉) (1) 
where  is a linear combination of vectors of training examples in T and  is the result of the learning phase. 
There is a large body of research in ML to induce the best classifiers from training data, but a real problem 
with medical data is represented by the heterogeneity of patients’ clinical attributes. These attributes 
participate to the final classification decision with different weights: the vector  in Equation (1). However, 
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these weights are rigidly derived from a linear combination of training examples. This is not sufficient to 
determine the relative weights between groups of very different clinical attributes. 
Finding optimal ways to combine heterogeneous groups of different attributes is thus a major problem both 
in precision medicine and in ML in general.
25
  
In this study, we used a simple method: combining kernel machines to learn predictors and RO
24
 to optimize 
their performances by changing the relative weight of groups of features. With RO, our method finds the 
combination of groups of attributes that yields to the best classification performance of our predictors over a 
validation set.   
Optimizing asks for a clear definition of the evaluation procedure. Evaluating classifiers is an important part 
of the learning process. Classifiers are evaluated on testing data sets that are completely separated from the 
training data. For unbalanced classes, performances are evaluated with positive predictive value (PPV), with 
sensitivity, and with a combination of the two. In ML, these measures are called Precision (P), Recall (R), and f-
measure, respectively. Hereafter, we indicate the value of the f-measure for a function	() on the testing data 
set  as: 
((), ) = 	 2 +  
where P and R are Precision and Recall of () on , respectively.  
We have thus a way to optimize predictors’ evaluation.  
Our method that combines kernel machines and RO is the following. First, clinical attributes are divided in 
groups according to clinical considerations. Each group has an associated sub-vector + in feature vectors 
representing patients. These vectors are obtained as a juxtaposition of sub-vectors, that is,  = ,, -, … ,
./. Second, the relative weight among groups of features is determined with a vector 0 = (0… , 0.)	of 
group weights. Hence, the kernel between two vectors of instances (), ()according to a weight vector 0 is 
defined as follows: 
(), (), 0 = 10+
+
〈+(), +()〉 10+
+
2  
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In this new setting, the kernel machine learns a classifier f that depends on , on the training set T and, finally, 
on 0, that is, (, 0, ). Next, we used RO to find 0.3 that maximizes the performance of the classifier 
(, 0, ) on a validation set V: 
0.3 = argmax8 ((, 0, ), )	 
Basically, the method sets an initial random vector 0, learns  (, 0, ) with the kernel machine, and 
determines its performance 9 = ((, 0:, ), ). Then, it starts a cycle where it randomly generates a 
perturbation vector ;,  learns (, 0 + ;, ), computes 9′ = ((, 0 + ;, ), ) and, if 9= > 9,  updates  
0 	← 0 + ; and 9 ← 9=. The cycle stops when after n perturbation vectors, no one produced 9= > 9. The final 
0 is retained as 0.3. 
Our method to find the best VTE risk predictors has two major benefits: first, it selects the best predictors 
on training data (,0.3, ); second, it determines relative weights 	0.3between groups of clinical 
attributes. These weights give useful insights on how predictors take their decisions. 
Patient dataset for VTE risk assessment 
Patient dataset for VTE risk assessment was attained by joint efforts between the PTV Bio.Ca.Re. (Policlinico 
Tor Vergata Biospecimen Cancer Repository) and the BioBIM (InterInstitutional Multidisciplinary Biobank, 
IRCCS San Raffaele Pisana).   
The patient dataset consisted of 1179 consecutive ambulatory cancer patients with primary or 
relapsing/recurrent solid cancers, who were prospectively followed under the appropriate Institutional ethics 
approval and in accordance with the principles embodied in the Declaration of Helsinki to investigate possible 
predictors of chemotherapy-associated VTE.  All patients were required to be at the start of a new 
chemotherapy regimen and no patient received thromboprophylaxis, according to current guidelines.  
Eligibility criteria are detailed in Supplementary Table 1.  Clinical characteristics and laboratory attributes of 
patients are summarized in Supplementary Table 2. 
Baseline blood samples were drawn at time of enrolment prior to chemotherapy start and tested for 
routine blood chemistry (Accelerator Total Lab Automation, Abbott Laboratories, Abbott Park, IL, USA) and 
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complete and differential blood cell counts (Coulter LH 750, Beckman Coulter, Miami, FL) in the facilities of the 
BioBIM of the IRCCS San Raffaele Pisana.  Estimated glomerular filtration rate (eGFR) was calculated using the 
simplified Modification Diet of Renal Disease study (MDRD) equation.
26
 
VTE was diagnosed at the Medical Oncology ward of the Department of Systems Medicine, PTV during 
scheduled chemotherapy visits, or at the occurrence of clinically suspected VTE. Deep venous thrombosis (DVT) 
was confirmed by venography or color-coded duplex sonography (in proximal DVT only).  Pulmonary embolism 
(PE) was diagnosed by spiral computed tomography displaying 1 or several low-attenuation areas that partly or 
completely filled the lumen of an opacified vessel.  Within 1 year of study entry, VTE occurred in 8% (29 PE and 
65 DVT) of patients.  Thirty-four (2.9%) patients had a previous history of VTE, and 5 (0.4%) had concurrent DVT 
on the first week of treatment.  Forty-one of 94 events were incidentally diagnosed (16 PE and 25 DVT) at time 
of restaging. 
All patients provided written informed consent, previously approved by our Institutional Ethics Committees. 
Experimental settings 
To test our methodology and to test default methods, the patient dataset was used in the following ways: 1) 
we divided clinical attributes in 9 groups; 2) we randomly divided the patient dataset in training and testing set, 
3) we rescaled continuous clinical attribute values to lay in the range [-0.5,0.5]; and, finally, 4) we filled missing 
clinical attribute values with the average of the attribute observed in the training set.  
Regarding the patient dataset division, group distribution was performed according to the clinical 
significance of the attributes included in the patient dataset.  In particular, demographic variables and tumor 
site and stage were individually considered given that they are generally recognized among the most important 
risk factors for VTE.
5,27
  Hematological attributes, including complete and differential blood cell counts,
8,28
 as 
well as neutrophil and platelet to lymphocytes ratios,
29
 were grouped all together.  Similarly, individual 
attributes concerning fasting blood lipids, glycemic indexes and liver and kidney function were clustered within 
three individual groups.  BMI and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) were 
considered within the same group, as the former might represent not only an obesity index, but is also 
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indicative of underweight in patients with cancer cachexia and, as such, can affect the performance status of a 
particular patient.  Supportive and anti-cancer drugs were collectively considered under the general definition 
of “drugs”.  In some experiments, tumor site, BMI, hemoglobin or erythropoiesis supporting agents, white 
blood and platelet counts were categorized as previously suggested,
8
 and grouped as Khorana score, which 
served as reference for subsequent analyses.  Details on groups of clinical attributes are reported in Figure 1. 
To apply ML models, the patient dataset was randomly divided in two groups:  
1) Training (Tr): 70% of the cases 
2) Testing (Ts): 30% of the cases 
The Training set was used to optimize the parameters 0  with RO and to learn the final risk predictor using 
the selected  0.3. RO was applied using 3-fold cross validation. The training set was divided in three parts and 
three runs were performed. For each step of the RO, we computed the performance of three learnt risk 
predictors on one of the three parts of the training set. These risk predictors were learnt using the remaining 
two parts. RO stops when the algorithms cannot improve a local maximum and selects 0.3 (see Table 1). The 
3 ML-RO are the top-3 f-measure in the training set for two different experiments including or not the 
“Khorana” group (Table 2). Then, we used 0.3 to learn the final risk predictor (, 0.3, ). The testing set 
was used to compute the final performance of our risk predictors (Table 2). 
Statistical analysis 
Time-to-event (TTE) was calculated from the enrolment date until VTE or the most recent follow-up visit 
(median TTE: 3 months). VTE-free survival curves were calculated by the Kaplan–Meier method and the 
significance level was assessed by log-rank test using a computer software package (Statistica 8.0, StatSoft Inc., 
Tulsa, OK). Cox-proportional hazards analyses were performed by a free web-based application 
(http://statpages.org/). 
This study had no external funding source.   
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RESULTS 
The weights of attribute classes for the ROs models are reported in Table 1.  Table 2 summarizes the results 
achieved using the top-3 models out of 5 runs obtained with RO using Khorana score (ML+RO-1-K,  ML+RO-2-K,  
and ML+RO-3-K), the top-3 models out of 5 runs obtained with RO without Khorana score (ML+RO-1,  ML+RO-
2,  and ML+RO-3), and 4 different baseline models: 1) Khorana k≥3: pure Khorana Score with cutoff at 3;
9
 2)  
Khorana-ML: an SVM VTE event predictor trained with a polynomial kernel of degree 2 that uses only the 
Khorana Score as feature; 3) Basic-ML-K; 4) Basic-ML. The two latter predictors are SVM VTE predictors where 
each group of clinical attributes has the same weight: Basic-ML-K uses Khorana score and Basic-ML does not 
use it.  As shown, a ML approach with RO was capable of improving VTE risk prediction compared to Khorana 
k≥3 or Khorana-ML as demonstrated by comparable precision (or positive predictive value – PPV) and 
considerably higher recall (or sensitivity) values, translating in a substantial improvement of the F-measure. 
These results were confirmed by Cox-proportional hazards survival analyses, in which Hazard Ratio (HR) and 
95% Confidence Intervals denoted the ratio of the probabilities of VTE occurrence in patients classified as at-
risk or low-risk by the ML models applied to the dataset.  As shown in Table 2, Khorana score, analyzed either 
as pure Khorana score (Khorana k≥3) or Khorana-ML, failed to achieve the statistical significance in risk 
estimation analysis when applied to the training set, whereas both basic-ML models, with (Basic-ML-K) or 
without (Basic-ML) inclusion of the Khorana score, yielded weak, but significant HRs (basic-ML: HR=1.69, 
p=0.040; Basic-ML-K: HR=1.91, p=0.019).  With only one exception (ML+RO-2), risk estimation for all ROs 
models (ML+RO-1-K,  ML+RO-2-K, ML+RO-3-K, ML+RO-1, and ML+RO-3) in the training set yielded HRs ranging 
from 2.03 to 3.36, which were all significant in terms of VTE risk prediction. 
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Table 1: Weights of attribute classes for the different models 
Method Sex Age Tumor site 
& stage 
BMI & ECOG Hematology 
 
Liver & 
kidney function 
Glycemic asset Blood lipid 
pattern 
Drugs Khorana 
Score 
Khorana-ML 0 0 0 0 0 0 0 0 0 1 
Basic-ML-K 1 1 1 1 1 1 1 1 1 1 
ML-RO-1-K 0.0963 0.0604 0.2218 0.9787 0.1161 0.0117 0.2334 0.0543 0.6735 0.0267 
ML-RO-2-K 0.0205 0.0304 0.8914 0.0577 0.0684 0.0256 0.0136 0.6652 0.1003 0.0000 
ML-RO-3-K 0.0581 0.0190 0.2437 1.2319 0.2636 0.2253 0.1265 0.3052 0.0523 0.0596 
Basic-ML 1 1 1 1 1 1 1 1 1 0 
ML-RO-1 0.0170 0.0035 0.1157 0.0538 0.0025 0.2511 0.7096 0.0046 0.1891 0 
ML-RO-2 0.1241 0.1144 0.3129 0.7672 0.0973 0.1420 0.0488 1.0548 0.2636 0 
ML-RO-3 0.1253 0.7654 0.2521 0.1808 0.0149 0.0616 0.0000 0.6499 0.3054 0 
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Table 2: Results of basic predictors and predictors based on machine-learning with random optimization 
Method Precision 
(PPV) 
Recall 
(Sensitivity) 
F-Measure HR (95%CI) Precision 
(PPV) 
Recall 
(Sensitivity) 
F-Measure HR (95%CI) 
Khorana (k>=3)* 0.122 0.075 0.093 1.86 (0.75-4.63) 0.136 0.111 0.122 2.16 (0.65-7.18) 
Khorana-ML 0.065 0.448 0.114 0.85 (0.51-1.41) 0.063 0.593 0.113 0.55 (0.26-1.19) 
         
Basic-ML-K 0.096 0.642 0.167 1.91 (1.12-3.29) 0.099 0.852 0.177 3.23 (1.12-9.33) 
ML-RO-1-K 0.126 0.761 0.217 3.04 (1.80-5.14) 0.105 0.741 0.184 2.61 (1.10-6.17) 
ML-RO-2-K 0.119 0.791 0.207 3.24 (1.80-5.84) 0.100 0.778 0.177 2.55 (1.03-6.33) 
ML-RO-3-K 0.115 0.687 0.197 2.10 (1.28-3.43) 0.112 0.704 0.193 2.73 (1.19-6.24) 
         
Basic-ML 0.091 0.537 0.155 1.69 (1.02-2.78) 0.078 0.593 0.137 1.09 (0.51-2.35) 
ML-RO-1 0.117 0.716 0.202 3.36 (1.94-5.84) 0.082 0.556 0.143 1.21 (0.57-2.59) 
ML-RO-2 0.115 0.731 0.198 1.45 (0.89-2.36) 0.122 0.889 0.214 6.92 (2.08-23.0) 
ML-RO-3 0.115 0.702 0.197 2.03 (1.23-3.35) 0.119 0.815 0.208 4.48 (1.70-11.8) 
 
*Patients with brain cancer (n=7) were excluded from the analysis (Khorana score not applicable) 
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Validation step was then performed on the testing set.  As summarized in Table 2, all ML models 
including the Khorana score resulted in an overall improvement of the performance measures for VTE risk 
prediction, both in terms of F-measure and HRs compared to the pure Khorana score, although the best 
fitting model in terms of clinical risk prediction was represented by ML+RO-3-K (HR=2.73, p=0.017).  On the 
other hand, the ML approach not including the Khorana score yielded significant results in the survival 
analyses only in ML-RO-2 (p=0.002) and ML-RO-3 (p=0.003) in which patients classified as at-risk had 
approximately 7 and 5-fold higher risks of developing VTE during chemotherapy administration than 
patients classified at no-risk. 
Kaplan–Meier curves for patients in the testing set stratified on the basis of Khorana k≥3 and Khorana-
ML are reported in Figure 2. As shown, despite a high precision, the Khorana score used at a cut-off ≥3 
points, as currently recommended,
9
 resulted in a very low sensitivity (only 3 of 27 VTE recorded events 
occurred in patients classified as at-risk) with a sub-optimal negative predictive value (NPV=0.928) and a 6-
month VTE-free survival rate not significantly different from that of low-risk patients (86% vs. 93%)(Figure 
2A).  Similar considerations can be drawn for the ML predictor using the Khorana feature alone (Figure 2B). 
Figure 3 depicts the Kaplan-Meier curves for the two best fitting models obtained with RO with (ML-RO-
3-K) or without (ML-RO-3) Khorana score in the testing set.  As shown, optimizing the relative importance 
(weight) of groups of clinical attributes resulted in an approximately 3 to 7-fold improvement of VTE risk 
prediction.  In particular, patients classified at-risk with ML-RO-3 had a significantly lower 6-month VTE-free 
survival (87%) compared to patients classified as low-risk (99%)(Figure 3B).   Kaplan-Meier survival curves of 
patients stratified with the other ML-RO models are reported in Supplementary Figure 1. 
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DISCUSSION  
The present study was designed to address the challenging task of VTE risk prediction in chemotherapy-
treated cancer outpatients. To this purpose, we used ML methods to build predictive models which 
consider different variable types, such as demographic, laboratory and clinical data (including therapies), 
routinely collected in EHRs, to retrospectively identify chemotherapy-associated VTE events in a general 
medical oncology centre population. 
Here, for the first time to our knowledge, we propose a precision medicine model to design VTE risk 
predictors for oncological patients treated with chemotherapy. In the algorithm here presented, we 
applied a combined approach of kernel machines and RO of performance of binary classifiers, 
hypothesizing that this method would have found combination of attributes yielding the best 
classification performance of our predictors over a validation set. Finally, we compared the predictive 
value of our learned models against the previously developed Khorana’s risk assessment tool. 
The results obtained demonstrated that this approach may be of advantage in the selection of VTE risk 
predictors over the currently accepted models and allowed us to draw a number of interesting 
considerations.  
First, the analysis of the variables collected from each patient identified several risk factors, not 
previously included in VTE risk assessments as per current guidelines.  In general, precision medicine 
approaches were better than generic ones. In fact, ML models using all the clinical attributes (Basic-ML-K, 
Basic-ML and ML-ROs) showed better F-measures and better HRs than generic models (pure Khorana score 
and Khorana-ML). This was verified on the training and, more importantly, on the testing set. Using 
additional clinical attributes is thus promising. 
Second, our approaches ML+ROs appeared extremely useful in designing VTE risk predictors. By 
optimizing the relative importance of groups of clinical attributes, we selected better risk predictors. It is 
obvious that on the training set f-measures of ML+ROs were better than Basic-ML as RO was carried out on 
the training set. It is less obvious that all ML-ROs outperformed Basic-MLs on the testing set in terms of f-
measure and that only ML-RO-1 was not superior to Basic-ML in terms of HR. 
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Most importantly, best scoring models in terms of both f-measure and HRs were also clinically plausible, 
as demonstrated by the finding that blood lipids and body mass index and performance status retained the 
strongest weight both in ML-RO-3-K and in ML-RO-2. This is consistent with the literature showing that low 
levels HDL-cholesterol
30
 and ECOG-PS
27,29
 proved good predictors of increased risk of VTE in chemotherapy-
treated cancer patients, in multiple regression models. Moreover, the ML-RO-2 model showed a weak 
association with tumor site and stage, and with drugs. This is not surprising, since both clinical attributes 
have also been associated with an increased risk of developing VTE.
8,12
 Indeed, advanced cancer, either 
locally (regional) or distant, represents per se an increased risk of VTE, 
31
 and we must acknowledge the 
role that anti-cancer drugs may play as thrombotic triggers in association with specific disease stages.
7,32
 
Indeed, anticancer therapies represent an important predisposing factor for VTE, capable of inducing an 
acquired thrombophilic condition,
7
 at a point that certain anti-cancer agents have been proposed to be 
included in the Khorana’s score in order to implement it, as in the case of the Protecht score.
12
 
Finally, the low f-measures obtained with our VTE risk predictors could be explained with the fact that 
our patient dataset was extremely unbalanced. Indeed, VTE occurred only in 8% of the cases. Hence, 
applying ML models to this dataset was extremely difficult, consistently with Larrañaga et al.
19
 Experiments 
with VTE predictors in general population have better performance,
21
 but the test set generally used, 
consisted of VTE cases paired to non-VTE controls, resulting in a more balanced set. Hence, VTE predictors 
in these studies
21
 cannot be compared to our study cohort, in which ambulatory cancer patients were 
consecutively enrolled and all VTE events were prospectively recorded by the oncologists during follow-up. 
Moreover, we must take into consideration that in hospitalized patients, cancer is connoted as one of the 
risk factors for VTE development, to such an extent that about 60% of occult cancers are diagnosed shortly 
after the diagnosis of an episode of unprovoked VTE.
33
  Conversely, in an oncological out-patient 
population, such as the one analyzed in our study, the attribute “cancer” is expanded to take into account 
individual groups of clinical attributes (i.e., cancer site and stage or administered anti-cancer or supportive 
drugs) that, as already stated, portend different degrees of clinically significant VTE risk, and might “weight” 
differently in the context of a ML algorithm. 
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There are, of course, some limitations that need to be acknowledged.  First, we must recognize that the 
model here reported was designed and validated on a dataset, which was not actually extracted from the 
EHR of single patients, due to privacy restrictions in reference to identifiable individuals.  As a matter of 
fact, the Medical Oncology Unit stores patients’ data in a digital format in EHRs, under data protection 
legislation. These records are highly customized into structured and non-structured fields including 
demographics, medical and family history, vital signs, medications, diagnostics and follow-up updating. 
Thus, all variables necessary for prediction are easily extractable from EHRs, once the model is validated for 
clinical use, as recently demonstrated by Lustig et al., who implemented the Khorana score with EHRs 
extraction to readily stratify patients into intermediate-high and low risk of VTE.
34
  Although glycemic 
profile and blood lipid pattern might not be always included in the pre-chemotherapy patient workout, we 
should take into consideration that these analytes are easy to perform and relatively inexpensive. This 
facilitates their inclusion in a validated clinical model with a negligible increase in health care costs.  
Another limitation might reside in the fact that the study was monocentric, thus validation was limited 
to a single institution.  However, primary aim of this study was not to present a new classifier that other 
Centers can adopt for clinical use, but rather to propose a different approach from that generally utilized in 
risk assessment models, based on the arbitrary assignment of a score according to association analysis.  
Here, we demonstrate that the use of ML algorithms and RO models might be of advantage in developing 
local classifiers capable of improving the original Khorana score, while retaining other advantages (e.g., 
recalculation based on data advance over time) in a perspective of precision medicine. 
 
 
CONCLUSIONS 
In conclusion, the method we propose to find the optimal VTE predictors has the unquestionable 
advantages of selecting the best predictors on training data and to determine the relative weights between 
groups of clinical attributes.  This model showed to outperform the general well-assessed Khorana score. 
Furthermore, it demonstrates that other variables must be considered in VTE risk evaluation, thus 
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strengthening the concept that data should not be considered singularly but in a more general association, 
as advocated by precision medicine. 
Furthermore, this risk stratification approach well fits with others who identified the need of developing 
new guidelines or of identifying topics deserving further ad hoc clinical trials,
35
 and might fill the gap left by 
current guidelines concerning VTE prophylaxis in intermediate risk patients. In this context, future 
application of our model might help oncologists in the delicate phase of decision making, by providing them 
with the great advantage of limiting observer subjectivity. 
Ongoing research involves: 1) the use of other optimization methods such as simulated annealing and 
genetic algorithms; and 2) the definition of a VTE risk prediction system. Of course, the prediction system 
will require larger sets of cases and controls to be acquired in future research projects.  Nonetheless, the 
results here reported add further evidence to the rising idea that locally trained models may be of 
advantage over the classic scoring schemes, which, in time, can lose their prediction value and become less 
accurate. 
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FIGURE LEGENDS 
 
Figure 1.  Groups of clinical attributes.  NLR: Neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; 
BMI: body mass index; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; 
eGFR: estimated glomerular filtration rate. The group “Drugs” includes all supportive and anti-
cancer agents listed in Supplementary Table 1. 
Figure 2. Kaplan–Meier curves of VTE-free survival of chemotherapy treated ambulatory cancer patients 
in the testing set.  Comparison between patients with low (dotted line) or high (solid line) risk of 
VTE based on pure Khorana score (Khorana k≥3)(Panel A) or a SVM VTE event predictor using 
only the Khorana Score as feature (Khorana-ML). 
Figure 3. Kaplan–Meier curves of VTE-free survival of chemotherapy treated ambulatory cancer patients 
in the testing set.  Comparison between patients with low (dotted line) or high (solid line) risk of 
VTE based on the two best fitting ML-RO models. Panel A: ML-RO-3-K. Panel B: ML+RO-2. 
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Kaplan–Meier curves of VTE-free survival of chemotherapy treated ambulatory cancer patients in the testing 
set.  Comparison between patients with low (dotted line) or high (solid line) risk of VTE based on pure 
Khorana score (Khorana k≥3)(Panel A) or a SVM VTE event predictor using only the Khorana Score as 
feature (Khorana-ML).  
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Kaplan–Meier curves of VTE-free survival of chemotherapy treated ambulatory cancer patients in the testing 
set.  Comparison between patients with low (dotted line) or high (solid line) risk of VTE based on the two 
best fitting ML-RO models. Panel A: ML-RO-3-K. Panel B: ML+RO-2.  
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Supplementary Table 1:  Inclusion and exclusion criteria 
Inclusion criteria 
Age >18 years 
Willingness to provide written informed consent 
Histologically confirmed diagnosis of malignancy 
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2 
Absolute neutrophil count ≥2,000 mm
-3
 
Platelet count ≥100,000 mm
-3
 
Hemoglobin level ≥9.5 g/dl 
Bilirubin level ≤1.5x upper normal limit (UNL) 
Alanine-aminotransferase and aspartate-aminotransferase ≤2.5x UNL in 
the absence, or ≤5x UNL in the presence of liver metastasis 
Normal renal function (serum creatinine ≤1.2 mg/dL) 
Exclusion criteria 
Therapeutic doses of any heparin before enrolment 
Concomitant treatment with anticoagulant or antiplatelet drugs 
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Supplementary Table 2:  Clinical and Laboratory attributes of the patient dataset 
Age, Mean ± SD (range) 62 ± 12 (18 – 85) Haematology and biochemical attributes 
Sex, N (%)    
Males 575 (49%) Blood cell counts  
Females 604 (51%) Red blood cells 4.3 ± 0.6 
BMI, Mean ± SD 25.5 ± 4.5 Haematocrit 35.8 ± 9.2 
ECOG-PS, N (%)  Hemoglobin 12.5 ± 1.6 
0 940 (80%) White blood cells 7.3 ± 2.9 
1 228 (19%) Neutrophils 4.9 ± 2.7 
2 11 (1%) Lymphocytes 1.7 ±0.9 
Primary tumor, N (%)  Platelets 254 ± 97 
Colorectal 316 (26.7%) Mean platelet volume 8.6 ± 1.1 
Gastric 53 (4.5%) Neutrophil/lymphocyte ratio 3.9 ± 4.2 
Esophageal 10 (0.9%) Platelet/lymphocyte ratio 188.1 ± 146.3 
Pancreatic 43 (3.7%)   
Biliary 18 (1.5%) Routine blood chemistry 
Lung  Blood urea nitrogen 36.6 ± 15.1 
Non small cell 183 (15.5%) Creatinine 0.9 ± 0.3 
Small cell 32 (2.7%) eGFR 91.0 ± 25.6 
Mesothelioma 5 (0.4%) Glucose 112.6 ± 43.6 
Breast 262 (22.2%) Insulin 27.9 ± 32.0 
Prostate 39 (3.3%) Glycated hemoglobin 6.1 ± 3.1 
Ovarian 33 (2.8%) Total bilirubin 0.6 ± 0.5 
Genitourinary 71 (6.0%) Alanine transaminase 22.5 ± 19.3 
Head-Neck 47 (4.0%) Aspartate transaminase 22.9 ± 17.1 
Sarcoma 24 (2.0) γ-glutamyl transferase 60.7 ± 129.2 
Brain 7 (0.6%) Triglycerides 136.9 ± 76.6 
Unknown 14 (1.2%) Total cholesterol 191.9 ± 47.0 
Other* 22 (1.9%) High-density lipoproteins 47. 8 ± 14.0 
Stage of disease, N (%)  Low-density lipoproteins 116.7 ± 39.8 
Primary 462 (39%)   
Relapsing/metastatic 717 (61%)   
Anti-cancer drugs, N (%)**    
Platinum compounds 580 (49.2%)   
Fluoropyrimidine 453 (38.4%)   
Anthracycline 201 (17.1%)   
Taxanes 212 (18%)   
Paclitaxel 89 (7.6%)   
Bevacizumab 153 (13.0%)   
Gemcitabine 170 (14.4%)   
Irinotecane 157 (13.3%)   
Pemetrexed 77 (6.5%)   
Herceptin 59 (5.0%)   
Anti-tyrosine kinase 14 (1.2%)   
Aromatase inhibitors 22 (1.9%)   
Supportive drugs, N (%)    
Erythropoiesis stimulating agents 39 (3.3%)   
Prophylactic myeloid growth factors 65 (5.5%)   
Corticosteroids 307 (26%)   
BMI: body mass index; ECOG-PS: Eastern Cooperative Oncology Group Performance Status. eGFR: estimated glomerular filtration 
rate.*Including melanoma (n=10), cancer of the small intestine (n=6), neuroendocrine tumors (n=2), thymomas (n=2) and one 
thyroid cancer. **11% neoadjuvant, 29% adjuvant and 60% metastatic treatments.
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